公开(公告)号：US10577317B2

公开(公告)日：2020-03-03

申请号：US16449103

申请日：2019-06-21

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John R. Snoonian ,  Harold Scott Wilkinson

IPC: C07D207/09

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

公开(公告)号：US20200024286A1

公开(公告)日：2020-01-23

申请号：US16403734

申请日：2019-05-06

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Milan CHYTIL ,  Sharon ENGEL ,  Taleen G. HANANIA ,  Vadim ALEXANDROV ,  Emer LEAHY

IPC: C07D498/04 ,  C07D231/56 ,  C07D498/20 ,  C07D498/14 ,  C07D498/22

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

公开(公告)号：US20190308990A1

公开(公告)日：2019-10-10

申请号：US16214985

申请日：2018-12-10

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Linghong Xie ,  Michele L.R. Heffernan ,  Philip Glyn Jones ,  Taleen G. Hanania

IPC: C07D493/04 ,  C07D307/87 ,  C07D311/76 ,  C07D313/08

Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

公开(公告)号：US10369134B2

公开(公告)日：2019-08-06

申请号：US16209412

申请日：2018-12-04

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Cabot Hopkins ,  Kenneth Stephen Koblan ,  John R. Snoonian ,  Harold Scott Wilkinson

IPC: A61K31/40 ,  A61P25/24

Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

公开(公告)号：US10196403B2

公开(公告)日：2019-02-05

申请号：US15663688

申请日：2017-07-28

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Taleen G. Hanania ,  Michele L. R. Heffernan ,  Philip Glyn Jones ,  Linghong Xie

IPC: C07D493/04 ,  C07D313/08 ,  C07D307/87 ,  C07D311/76

Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

公开(公告)号：US10196399B2

公开(公告)日：2019-02-05

申请号：US15625604

申请日：2017-06-16

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Michele L. R. Heffernan ,  Larry Wendell Hardy ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat ,  Kerry L. Spear

IPC: C07D487/04 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D487/14 ,  C07D487/18 ,  C07D491/147 ,  C07D491/20 ,  C07D491/22 ,  C07D498/04 ,  C07D487/10

Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.

公开(公告)号：US20180333373A1

公开(公告)日：2018-11-22

申请号：US15873540

申请日：2018-01-17

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Thomas Jerussi ,  Qun Kevin FANG ,  Mark G. CURRIE

IPC: A61K31/135 ,  C07C211/42

CPC classification number: A61K31/135 ,  C07B2200/07 ,  C07C211/42 ,  C07C2602/10

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

公开(公告)号：US10077243B2

公开(公告)日：2018-09-18

申请号：US14299364

申请日：2014-06-09

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Larry Wendell Hardy ,  Michele L. R. Heffernan ,  Frank Xinhe Wu ,  Lakshmi D. Saraswat ,  Kerry L. Spear

IPC: A61K31/517 ,  C07D487/04 ,  C07D239/88 ,  C07D403/06 ,  C07D405/06 ,  C07D417/06 ,  C07D471/04 ,  C07D487/20 ,  C07D401/14 ,  C07D413/04 ,  C07D471/14 ,  C07D471/20 ,  C07D487/08 ,  C07D491/20 ,  C07D498/04

CPC classification number: C07D239/88 ,  C07D401/14 ,  C07D403/06 ,  C07D405/06 ,  C07D413/04 ,  C07D417/06 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D487/04 ,  C07D487/08 ,  C07D487/20 ,  C07D491/20 ,  C07D498/04

Abstract: Provided herein are compounds of formula (I): and pharmaceutical compositions thereof, useful for the treatment of disorders mediated by metabotropic glutamate receptor 5.

公开(公告)号：US20180093974A1

公开(公告)日：2018-04-05

申请号：US15819372

申请日：2017-11-21

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Linghong Xie ,  Philip Glyn Jones ,  Kerry L. Spear ,  Noel Aaron Powell ,  Taleen G. Hanania ,  Vadim Alexandrov

IPC: C07D405/04 ,  C07D413/04 ,  C07D493/04 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D405/04 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D493/04

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

公开(公告)号：US09758529B2

公开(公告)日：2017-09-12

申请号：US15041827

申请日：2016-02-11

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Milan Chytil ,  Sharon Engel ,  Taleen G. Hanania ,  Vadim Alexandrov ,  Emer Leahy

IPC: C07D498/04 ,  C07D498/14 ,  C07D498/20 ,  C07D498/22

CPC classification number: C07D498/04 ,  C07D498/14 ,  C07D498/20 ,  C07D498/22

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.